Skip to main content
Premium Trial:

Request an Annual Quote

ILSI Tox Expert: FDA Should Exercise Restraint When Composing Array-Based Toxicology Guide

Premium

The FDA’s plan to standardize expression-based pre-clinical toxicology data “potentially has some positive implications,” said William Pennie, director of molecular and investigative toxicology at a Pfizer R&D outpost in Groton, Conn.

However, he cautioned that the standards should be as flexible as possible. “Now is not the time for [the FDA to be] be overly prescriptive in terms of guidelines,” said Pennie, who also chairs a committee sponsored by the International Life Sciences Institute that studies the application of genomics to mechanism-based risk assessment. (According to the FDA, ILSI will be one of several bodies asked to help the FDA review the new toxicology standards.) “This is a rapidly evolving area of technology and science, and I think we need to maintain significant flexibility, and be receptive to new approaches and methodologies, analytical methods, and ... new technical platforms.”

Asked whether the FDA dove into the project too soon, Pennie said the answer depends on how prescriptive the guidelines will be in the first place. “I think that general guidelines around the resolution of information that the agency would like to have submitted — the way that a sponsor reports the protocols of their experiments under analytical methods — those kinds of things are fine,” he explained. However, if the standards end up directing pharma experiments, “then I would argue that [the goal of a standard] is premature.”

Will this guidance spur Pfizer to change the way it performs gene expression-based pre-clinical toxicology studies, or embolden the company to begin submitting these kinds of data to the FDA? “We may or may not decide that it’s a better environment to be performing these experiments,” said Pennie. Pfizer’s R&D decisions are not driven “very much by fear of regulatory repercussions at the moment.”

— KL

 

Filed under

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.